Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford, Oxford University Hospitals NHS Foundation Trust and the Patient experience healthcare company Oneview Healthcare signed a research and development (R&D) agreement for clinical pathways, following the success of a Prostate Cancer Pathway pilot.

Image courtesy of Medical Sciences Division and John Cairns

Oneview Healthcare PLC (Oneview) have announced a partnership with The Chancellor Masters and Scholars of the University of Oxford and Oxford University Hospitals NHS Foundation Trust (OUH) to continue research and development on a clinical pathways product. The solution will ease administrative burden, digitise currently paper-based processes and ultimately expedite wait times and access to care.

In conjunction with a leading engineering company, University of Oxford, OUH and Oneview entered into a partnership in an agreement dated 31 January 2017 to pilot a digital pathways for prostate cancer to improve patient outcomes and deliver cost efficiencies to health systems. That pilot’s success is the catalyst for the new agreement. The prostate cancer pilot succeeded in the areas of clinical staff uptake, meeting or exceeding wait time goals, and providing an easy-to-use interface the clinicians embraced. The new research and development will focus on expanding the technology to include full commercial deployment at Oxford via a SMART on FHIR1 integration and expansion of scope to other types of  cancer (beyond prostate cancer). The partners expect to commercialise the new products globally, helping healthcare organisations around the world to digitise care pathways, connecting information across systems to drive clinical transformation and reduce variation.

Professor Freddie Hamdy, Head of Oxford University's Nuffield Department of Surgical Sciences and Divisional Director of Surgery and Oncology at OUH, commented: 'This is one of the most innovative projects Oxford have done in the past few years.'

James Fitter, CEO of Oneview Healthcare stated: 'This has been a textbook case of agile development with our team working side-by-side with the Oxford clinicians to solve real-world problems. Combining Oxford’s clinical expertise with our software innovation and integration skills has proved a powerful combination. We are delighted with the results of the pilot and the opportunity to move forward in developing other life-changing cancer pathways. We take pride in our partnership with Oxford University and OUH, and are honoured that we can all work together to advance technology that has so much potential to changes lives around the world.'

1 SMART on FHIR is an open standards-based platform for medical apps designed to promote interoperability

Press release courtsey of Oneview.

Similar stories

New reporting guidelines to bridge the gap from development to implementation in clinical artificial intelligence

Innovation Research

In a correspondence to Nature Medicine, a team of Oxford-led academics describe upcoming new guidelines to improve the reporting of early clinical stage (or first-with-human) evaluation of decision support systems driven by artificial intelligence.

Cochrane ENT awarded NIHR funding for COVID-19 project

Awards and appointments Coronavirus COVID-19 Research

Cochrane ENT at the Nuffield Department of Surgical Sciences has been awarded funding by the National Institute for Health Research (NIHR) to complete a suite of living systematic reviews investigating the effectiveness and safety of interventions to prevent and treat loss of smell after COVID-19 infection.

First peer-reviewed results of phase 3 human trials of Oxford coronavirus vaccine demonstrate efficacy

Coronavirus COVID-19 Publication Research

Today University of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%.

Applications for Oxford-Wolfson-Marriott-Patel Scholarship now open

Awards and appointments Department Research

The Nuffield Department of Surgical Sciences (NDS) are pleased to confirm that one scholarship will be available for Home (UK) and Republic of Ireland (ROI) candidates for the DPhil in Surgical Sciences, starting in Michaelmas Term 2021.

Oxford University breakthrough on global COVID-19 vaccine

Coronavirus COVID-19 Research

The University of Oxford, in collaboration with AstraZeneca plc, today announces interim trial data from its Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection.

Transplant kidney survival rate improves with new method of transportation

Publication Research

New research by the Consortium for Organ Preservation in Europe (COPE) has found that a new method to transport donor kidneys, which uses a combination of cold perfusion with oxygen, can significantly improve transplant results, with less graft failure, better function and lower rejection of the kidney when compared to cold perfusion alone. For patients who need a kidney transplant this is a big step forward. The study, carried out in Belgium, The Netherlands and the UK, was published today in The Lancet.